ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the treatment of advanced hepatocellular carcinoma. Eligible participants will be divided into two groups based on their treatment plans: one receiving ICIs combined with anti-VEGF drugs, and the other receiving ICIs combined with anti-VEGF drugs alongside interventional therapy, which includes C-TACE, D-TACE, and HAIC. The specific number and interval of interventional thera

Trial Details

NCT ID
NCT07157969
Phase
PHASE2
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Lenvatinib
  • Pembrolizumab
  • Atezolizumab
  • Bevacizumab
  • Camrelizumab
  • Apatinib
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Subjects voluntarily participate in the study, provide written informed consent, demonstrate good compliance, and are cooperative with follow-up.
  • Age ≥18 years at the time of signing informed consent, regardless of gender.
  • Diagnosis of hepatocellular carcinoma confirmed by imaging (according to AASLD criteria), histology, or cytology.
  • BCLC Stage B or C.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →